TheraRadar
← Back
Data updated: Jul 17, 2026

Teva

Generics
CardiovascularRespiratoryNeurology Execution: Needs Improvement

Teva is a generic drug manufacturer focused on Cardiovascular, Respiratory, Neurology. Key products include MICAFUNGIN.

1948
Since
774
Drugs
-
Trials
7
New Drugs (2yr)
Modality:
22 Small Molecules 1 Biologics

FDA Novel Drug Designations

(2016-2018)
3 Novel 1 First-in-Class 1 Orphan 1 Priority Review
See 3 novel approvals →
2018 AJOVY (FREMANEZUMAB-VFRM) Priority Review
2017 AUSTEDO (DEUTETRABENAZINE) Orphan
2016 CINQAIR (RESLIZUMAB) First-in-Class

Teva at a Glance

  • Fast trial execution (18 months median completion)

Teva's Key Drugs

Teva's core commercial portfolio centers on FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, spanning Cardiovascular and Respiratory — its most strategically important drugs approved in the last 15 years.

FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE
Respiratory

Hay Fever

Approved 2020
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE
CNS

Major Depressive Disorder

Serotonin transporter Approved 2012
NAPROXEN AND ESOMEPRAZOLE MAGNESIUM
Immunology

Osteoarthritis

COX-1 Approved 2020
DICLOFENAC SODIUM AND MISOPROSTOL
Immunology

Osteoarthritis

COX-1 Approved 2012
PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE
Metabolic

Obesity

Approved 2024

Teva's Recent FDA Approvals

Teva secured 7 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

PONLIMSI BLA
2026-03-27
denosumab-adet
DULOXETINE HYDROCHLORIDE NDA
2026-02-27
duloxetine hydrochloride
ROCURONIUM BROMIDE NDA
2025-10-24
rocuronium bromide
Routine tracheal intubation
FAMOTIDINE NDA
2025-07-16
famotidine
1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine tablets are a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence.
ROCURONIUM BROMIDE NDA
2025-06-09
rocuronium bromide
Routine tracheal intubation
DAPTOMYCIN NDA
2024-11-21
daptomycin
Skin and Skin Structure Infections
BORTEZOMIB NDA
2024-08-26
bortezomib

Teva's Therapeutic Areas

Teva's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Respiratory, across 1 biologic and 22 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 25%
49 drugs
Respiratory 21%
15 drugs Phase 3: 32 Phase 2: 8 Phase 1: 11
Neurology 20%
25 drugs Phase 3: 18 Phase 2: 4 Phase 1: 6
Dermatology 16%
27 drugs Phase 3: 7
Oncology 16%
27 drugs Phase 3: 3 Phase 2: 1 Phase 1: 12

Teva's Top Competitors

Teva's closest competitors by therapeutic-area and drug-target overlap include Bayer, Pfizer, and Novartis. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Bayer big-pharma
Oncology, Cardiovascular, Respiratory, Dermatology
Pfizer big-pharma
Oncology, Neurology, Dermatology
Novartis big-pharma
Oncology, Cardiovascular, Respiratory
GE HEALTHCARE specialty
Neurology, Cardiovascular, Oncology, Respiratory
Merck big-pharma
Oncology, Cardiovascular, Respiratory

Teva Pipeline Snapshot

Teva has 102 active clinical programs from ClinicalTrials.gov — 60 Phase 3, 13 Phase 2 and 29 Phase 1.

60
Phase 3
13
Phase 2
29
Phase 1

Phase 3 Readout Calendar Pro

1 Phase 3 trial with confidence-graded primary completion dates.

Full calendar →
Q4 2025
Tapinarof Cream 1%
Plaque Type Psorisis
Completed · awaiting NCT06742957

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE leads revenue
  • • 5 key drugs tracked

Trial Catalysts

  • • Cardiovascular pipeline focus
  • • 1 Phase 3 readout tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 2/4 completed
  • • Speed: 18 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges